Clinical Trial Update: A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial evaluating four doses of an investigational PDE4 inhibitor in patients with chronic obstructive pulmonary disease. The study, condu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PDE4 inhibitor (investigational)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED